Cresco Labs Inc. (CSE:CL) (OTCQX: CRLBF) (FSE:6CQ) Q3 2022 revenue was $210 million, down 2% year-over-year.
Q3 2022 Financial Highlights
Gross profit of $99.1 million or 47% of revenue, compared to gross profit of $108.3 million or 50% of revenue in Q3 2021.
Adjusted EBITDA of $41.7 million, compared to $56.4 million in Q3 2021.
Net loss was $3.2 million compared to loss of $263.5 million in Q3 2021.
On November 4, 2022, Cresco Labs announced planned divestitures of Cresco and Columbia Care assets in New York, Illinois and Massachusetts to entities controlled by Sean Combs for a total purchase price of up to $185 million; closing is expected to occur concurrently with …